Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD200-IgG1
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CD200-IgG1 is a fully humanized monoclonal antibody of the IgG1 isotype that targets CD200, an immunosuppressive molecule overexpressed on acute myeloid leukemia (AML) stem cells. CD200 acts as an immune checkpoint by interacting with its receptor (CD200R) on immune cells, creating an immunosuppressive microenvironment that facilitates leukemic cell survival and immune escape. CD200-IgG1 works by blocking the CD200/CD200R interaction, thereby reversing this suppression and restoring immune cell activity. Additionally, the IgG1 backbone of the antibody enables the induction of antibody-dependent cellular cytotoxicity (ADCC) by NK cells and antibody-dependent cellular phagocytosis (ADCP) by macrophages. Developed by the Oncology Research for Biologics and Immunotherapy Translation (ORBIT) department at the University of Texas MD Anderson Cancer Center, CD200-IgG1 has demonstrated the ability to eliminate CD200-positive AML disease in humanized mouse models.
- Other names
- anti-CD200 mAbanti-CD-200 mAbanti-CD 200 mAb
02
Targets
Cell surface glycoprotein CD200 receptor familyCD200R1 (CD200 receptor 1)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)FCGRT (Neonatal crystallizable fragment receptor)CD200
Beyond the preview
Go deeper on CD200-IgG1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD200-IgG1.